Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam

Congenital rubella syndrome is a constellation of birth defects that can have devastating consequences, impacting approximately 100,000 births worldwide each year. The incidence much lower in countries routinely vaccinate their population. In the US, postnatal immunization susceptible women an important epidemiological strategy for prevention as Center Disease Control (CDC) does not recommend administering this vaccine during pregnancy due to its nature live attenuated virus vaccine. However, concerns co-administration with other immunoglobins (i.e., Rhogam) could compromise efficacy has produced warnings delay administration vaccination postpartum, leaving disease subsequent pregnancies. We aimed address whether measles, mumps, and (MMR) Rhogam decreased antibody responses compared those receiving only MMR vaccination. This retrospective cohort study utilized clinical data from 78 subjects who received after delivery 45 alone. Maternal demographics, complications status at start were recorded analysis. Overall, two cohorts had similar baseline characteristics; however, parity was noted participants both Rhogam. Making assessments based on maternal IgG index next pregnancy, we observed 88% + group positive serology scores, which significantly different 80% rate MMR-vaccine-only (p = 0.2). conclusion, no differences immunity pregnancies mothers given concurrently. Given these findings, against vaccines combination appear unwarranted.